Skip to content
10-Q

Quarterly Report

Acorda Therapeutics, Inc.

0000950170-24-059114

← back to feed
Filed
May 14, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 10, 2024 1.24M sh
Shares Diluted Q1 2024 · Mar 31, 2024 1.24M sh
Shares Diluted restated Q1 2024 · Mar 31, 2023 1.24M sh
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$20.19M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$7.02M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $9.36M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $29.98M
Cash And Equivalents Q1 2024 · Mar 31, 2023 $30.26M
Cash And Equivalents Q1 2024 · Dec 31, 2022 $37.54M
Stockholders Equity Q1 2024 · Mar 31, 2024 −$185.77M
Stockholders Equity Q1 2024 · Dec 31, 2023 −$157.96M
Current Liabilities Q1 2024 · Mar 31, 2024 $223.94M
Current Liabilities Q1 2024 · Dec 31, 2023 $227.77M
Current Assets Q1 2024 · Mar 31, 2024 $48.45M
Current Assets Q1 2024 · Dec 31, 2023 $74.79M
Total Assets Q1 2024 · Mar 31, 2024 $81.58M
Total Assets Q1 2024 · Dec 31, 2023 $108.53M
Eps Diluted Q1 2024 · Mar 31, 2024 −$22.06
Eps Diluted restated Q1 2024 · Mar 31, 2023 −$13.54
Eps Basic Q1 2024 · Mar 31, 2024 −$22.06
Eps Basic restated Q1 2024 · Mar 31, 2023 −$13.54
Sga Expense Q1 2024 · Mar 31, 2024 $28.37M
Sga Expense Q1 2024 · Mar 31, 2023 $22.51M
Rd Expense Q1 2024 · Mar 31, 2024 $954K
Rd Expense Q1 2024 · Mar 31, 2023 $1.39M
Net Income Q1 2024 · Mar 31, 2024 −$27.4M
Net Income Q1 2024 · Mar 31, 2023 −$16.82M
Operating Income Q1 2024 · Mar 31, 2024 −$19.63M
Operating Income Q1 2024 · Mar 31, 2023 −$11.48M
Cost Of Revenue Q1 2024 · Mar 31, 2024 $3.71M
Cost Of Revenue Q1 2024 · Mar 31, 2023 $3.23M
Revenue Q1 2024 · Mar 31, 2024 $20.29M
Revenue Q1 2024 · Mar 31, 2023 $22.26M